Head-To-Head Contrast: CRISPR Therapeutics (NASDAQ:CRSP) & Exscientia (NASDAQ:EXAI)

Exscientia (NASDAQ:EXAI) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Insider & Institutional Ownership

41.6% of Exscientia shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 16.4% of Exscientia shares are held by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Exscientia and CRISPR Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exscientia	0	4	0	0	2.00
CRISPR Therapeutics	2	8	9	0	2.37

Exscientia currently has a consensus price target of $7.00, suggesting a potential upside of 52.17%. CRISPR Therapeutics has a consensus price target of $75.19, suggesting a potential upside of 65.72%. Given CRISPR Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Exscientia.

Profitability

This table compares Exscientia and CRISPR Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exscientia	-620.99%	-37.56%	-26.19%
CRISPR Therapeutics	N/A	-13.85%	-11.69%

Risk and Volatility

Exscientia has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500.

Earnings & Valuation

This table compares Exscientia and CRISPR Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exscientia	$21.02 million	26.45	-$181.56 million	($1.31)	-3.51
CRISPR Therapeutics	$200.00 million	19.26	-$153.61 million	($2.72)	-16.68

CRISPR Therapeutics has higher revenue and earnings than Exscientia. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.

Summary

CRISPR Therapeutics beats Exscientia on 10 of the 14 factors compared between the two stocks.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.